genovis产品代理
genovis产品代理
Genovis 的业务理念是为生物制药和研究行业的客户提供工具，以促进和节省新治疗方法和诊断方法的开发时间。 Genovis酶产品，被称为SmartEnzymes，被世界各地的科学家使用，创新的产品形式促进了生物药物的开发和质量控制。
通过在 2020 年收购 QED Bioscience，产品组合已扩展到包括用于研究、生物药物开发和诊断分析的抗体和试剂。在 www.qedbio.com 上阅读有关 QED 的更多信息
Genovis 研发活动的基石是客户关系，它使产品开发能够满足客户需求。同样有价值的是与专注于表征新酶、为新目标开发新工作流程和抗体的学术团体的合作。
The Genovis Group consists of Genovis AB, Sweden, and the wholly owned subsidiary Genovis Inc., USA. The company has aprox. 2,600 shareholders and the company's shares are listed on Nasdaq First North Growth Market. Find more information at Investor Relations.
Genovis’ business concept is to offer customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Genovis enzyme products, known as SmartEnzymes, are used by scientists all over the world and the innovative product formats facilitate development and quality control of biological drugs.
Through the acquisition of QED Bioscience in 2020 the product portfolio has expanded to include antibodies and reagents for use in research, biological drug development and diagnostic assays. Read more about QED at www.qedbio.com
A cornerstone of Genovis’ R&D activities is customer relations that enables product development to meet customer needs. Just as valuable is the collaboration with academic groups that focus on characterizing new enzymes, developing new workflows and antibodies for novel targets.
